H. Lundbeck A/S

HLUN B

DK0061804770

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 16:20:00 10/04/2026 BST			5-day change	1st Jan Change
40.38 ^DKK	+1.36%		-0.98%	-6.44%

03-23	H. Lundbeck Price Target Down as AlphaValue/Baader Europe Expects Patent Expirations to Weigh on Growth	MT
03-20	H Lundbeck: Markets need more proof of growth promise

Deutsche Bank Lowers Price Target for Lundbeck to 40 Danish Kroner (44), Maintains Hold Recommendation

Published on 02/17/2026 at 01:37 pm GMT

Finwire - Translated by Marketscreener - See original

H. LUNDBECK A/S

+1.36%

Deutsche Bank has lowered its price target for Lundbeck to 40 Danish kroner (previously 44), while reiterating its hold recommendation.

Latest news about H. Lundbeck A/S

03-23	H. Lundbeck Price Target Down as AlphaValue/Baader Europe Expects Patent Expirations to Weigh on Growth	MT
03-20	H Lundbeck: Markets need more proof of growth promise
03-18	H. Lundbeck A/S Announces Board and Board Committee Appointments	CI
03-18	H. Lundbeck A/S Approves Dividend for the Accounting Year 2025	CI
03-18	H. Lundbeck A/S - Shareholder/Analyst Call
03-16	H. Lundbeck A/S Advances Parkinson's Research With New Phase 1b Data On Lu AF28996 And Presents Updates On Multiple System Atrophy Programs	CI
03-16	Lundbeck presents new Phase 1b Parkinson's data	FW
03-10	H. Lundbeck A/S Appoints Markus Kede as Senior Vice President and Chief AI Officer and Joins Executive Leadership Team, Effective July 1, 2026	CI
03-10	H. Lundbeck Names Chief Artificial Intelligence Officer	MT
03-10	Lundbeck appoints Head of AI	FW
03-09	H. Lundbeck Randomizes Last Patient in Late-stage Trial for Amlenetug	MT
03-09	Lundbeck completes recruitment for Phase 3 MSA study	FW
03-09	H. Lundbeck A/S Announces Last Patient Randomized in Phase 3 Mascot Trial	CI
03-05	Nordea Resumes Coverage of Lundbeck With Buy Rating – Too Cheap to Ignore	FW
03-05	Nordea Resumes Coverage of Lundbeck with Buy Rating and Price Target of 55 Danish Kroner	FW

H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimerâ€™s disease, Bipolar disorder, depression, epilepsy, Huntingtonâ€™s disease, Parkinsonâ€™s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimerâ€™s disease, Azilect for the treatment of Parkinsonâ€™s disease, Xenazine for the treatment of Huntingtonâ€™s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.

Employees

5,039

Sector

Pharmaceuticals

Calendar

05-13 - Earnings release - Q1 2026

More about the company